Gennaro Scutiero

Gennaro Scutiero

Auto-generated profile, based on publicly available information

Gennaro Scutiero

Department of Medical Sciences, Institute of Obstetrics and Gynecology University of Ferrara Ferrara Italy

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
GSG. Scutiero
G. Scutiero
GVGiuseppe Vizzielli
Giuseppe Vizzielli
CTCristina Taliento
Cristina Taliento
GBG. Bernardi
G. Bernardi
RMR. Martinello
R. Martinello
PGP. Greco
P. Greco

5 March 2024 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
CTCristina Taliento
Cristina Taliento
GSG. Scutiero
G. Scutiero
Martina ArcieriMartina Arcieri
Martina Arcieri
GPG. Pellecchia
G. Pellecchia
VTVeronica Tius
Veronica Tius
GVGiuseppe Vizzielli
Giuseppe Vizzielli
This systematic review (SR) and meta-analysis aims to compare the surgery-related results and oncological outcomes between SH and RH in patients with early-stage cervical cancer. We systematically searched databases including PubMed, Embase and Cochrane to collect studies that compared oncological and surgery-related outcomes between SH and RH groups in patients with stage IA2 and IB1 cervical cancer. A random-effect model calculated the weighted average difference of each primary outcome via Review Manager V.5.4. Seven studies comprising 6977 patients were included into our study. For oncological outcomes, we found no statistical difference in recurrence rate [OR = 0.88; 95% CI (0.50, 1.57); P = 0.68] and Overall Survival (OS) [OR = 1.23; 95% CI (0.69, 2.19), P = 0.48]. No difference was detected in the prevalence of positive LVSI and lymph nodes metastasis between the two groups. Concerning surgery-related outcomes, the comprehensive effects revealed that the bladder injury [OR = 0.28; 95% CI (0.08, 0.94), P = 0.04] and bladder disfunction [OR = 0.10; 95% CI (0.02, 0.53), P = 0.007] of the RH group were higher compared to the SH group. This meta-analysis suggested there are no significant differences in terms of both recurrence rate and overall survival among patients with stage IA2-IB1 cervical cancer undergoing SH or RH, while the SH group has better surgery-related outcomes. These data confirm the need to narrow the indication for RH in early-stage cervical cancer.

4 November 2023 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
CTCristina Taliento
Cristina Taliento
Stefano RestainoStefano Restaino
Stefano Restaino
GSGennaro Scutiero
Gennaro Scutiero
Martina ArcieriMartina Arcieri
Martina Arcieri
GBGiulia Bernardi
Giulia Bernardi
GVGiuseppe Vizzielli
Giuseppe Vizzielli
PIPAC consists in delivering normothermic chemotherapy solution directly into the peritoneal cavity as an aerosol under pressure. Currently PIPAC is considered as a palliative treatment for patients suffering from non-resectable peritoneal carcinomatosis. We performed a SR to assess tolerance and response of this novel method among patient with OC. We searched electronic database PubMed, Embase, Web of Science, Clinical Trials.gov. We only included clinical studies reporting PIPAC with cisplatin and doxorubicin in patients with ovarian cancer. This systematic review included 4 studies. In 3 studies all patients were pretreated with cytoreductive surgery, in 1 study surgery was performed in 8/34 (23 %) patients. Mean PCI at first PIPAC procedure ranged from 16.3 to 19.6. All studies reported the proportion of patients with ascites at the first PIPAC with a pooled rate of 48,3 %. Pooled rate of CTCAE Grade 3 toxicity calculated on the total number of PIPAC was 6 % and Grade 4 was 0.9 %. One study reported two cases of small bowel perforation related or potentially related to PIPAC. On study reported a cumulative survival after 400 days of 62 % and a mean actuarial survival time of all patients who underwent PIPAC of 442 days. In another study the mean time to progression was 144 days (95 % CI 122-168 days). This systematic review demonstrated that PIPAC with cisplatin and doxorubicin appear to have a good safety profile with low toxicity and encouraging trend in terms of overall survival.

1 January 2012 in JSLS : Journal of the Society of Laparoscopic & Robotic Surgeons
Verified
Journal Article
Open access
GSGennaro Scutiero
Gennaro Scutiero
PGPietro Di Gioia
Pietro Di Gioia
ASAlessandra Spada
Alessandra Spada
PGPantaleo Greco
Pantaleo Greco
Primary ovarian ectopic pregnancy, i.e., the implantation of the gestational sac in the ovary, is one of the rarest forms of ectopic pregnancy. Its incidence after natural conception ranges from 1 in 2000 to 1 in 60 000 deliveries and accounts for 3% of all ectopic pregnancies. The diagnosis is intricate and based on surgical and histopathological observations. The management is, in spite of medical improvement, based on surgery. We present a case of a 10-wk ectopic ovarian pregnancy managed laparoscopically, and we describe, through a review of the literature, the specific symptomatology, diagnostic criteria, and treatment of this particular pathology.

1 November 2017 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
MMMARIA MATTEO
MARIA MATTEO
ECE. Cicinelli
E. Cicinelli
Margherita NeriMargherita Neri
Margherita Neri
RCR. Carrubba
R. Carrubba
FCF.A. Carpagnano
F.A. Carpagnano
GSG. Serviddio
G. Serviddio

1 January 2016 in Journal of Perinatal Medicine
Verified
Journal Article
Closed access
LNLuigi Nappi
Luigi Nappi
FTFederica Trezza
Federica Trezza
PBPantaleo Bufo
Pantaleo Bufo
IRIrene Riezzo
Irene Riezzo
ETEmanuela Turillazzi
Emanuela Turillazzi
PGPantaleo Greco
Pantaleo Greco
Aim: To compare different classification systems in a cohort of stillbirths undergoing a comprehensive workup; to establish whether a particular classification system is most suitable and useful in determining cause of death, purporting the lowest percentage of unexplained death.Methods: Cases of stillbirth at gestational age 22–41 weeks occurring at the Department of Gynecology and Obstetrics of Foggia University during a 4 year period were collected. The World Health Organization (WHO) diagnosis of stillbirth was used. All the data collection was based on the recommendations of an Italian diagnostic workup for stillbirth. Two expert obstetricians reviewed all cases and classified causes according to five classification systems.Results: Relevant Condition at Death (ReCoDe) and Causes Of Death and Associated Conditions (CODAC) classification systems performed best in retaining information. The ReCoDe system provided the lowest rate of unexplained stillbirth (14%) compared to de Galan-Roosen (16%), CODAC (16%), Tulip (18%), Wigglesworth (62%).Conclusion: Classification of stillbirth is influenced by the multiplicity of possible causes and factors related to fetal death. Fetal autopsy, placental histology and cytogenetic analysis are strongly recommended to have a complete diagnostic evaluation. Commonly employed classification systems performed differently in our experience, the most satisfactory being the ReCoDe. Given the rate of “unexplained” cases, none can be considered optimal and further efforts are necessary to work out a clinically useful system.